ABSTRACT
BACKGROUND@#Peritoneal fibrosis is the primary reason that patients with end-stage renal disease (ESRD) have to cease peritoneal dialysis. Peritonitis caused by Gram-negative bacteria such as Escherichia coli (E. coli) were on the rise. We had previously shown that matrine inhibited the formation of biofilm by E. coli. However, the role of matrine on the epithelial-mesenchymal transition (EMT) in peritoneal mesothelial cells under chronic inflammatory conditions is still unknown.@*METHODS@#We cultured human peritoneal mesothelial cells (HPMCs) with lipopolysaccharide (LPS) to induce an environment that mimicked peritonitis and investigated whether matrine could inhibit LPS-induced EMT in these cells. In addition, we investigated the change in expression levels of the miR-29b and miR-129-5p.@*RESULTS@#We found that 10 μg/ml of LPS induced EMT in HPMCs. Matrine inhibited LPS-induced EMT in HPMCs in a dose-dependent manner. We observed that treatment with matrine increased the expression of E-cadherin (F = 50.993, P < 0.01), and decreased the expression of alpha-smooth muscle actin (F = 32.913, P < 0.01). Furthermore, we found that LPS reduced the expression levels of miR-29b and miR-129-5P in HPMCs, while matrine promoted the expression levels of miR-29b and miR-129-5P.@*CONCLUSIONS@#Matrine could inhibit LPS-induced EMT in HPMCs and reverse LPS inhibited expressions of miR-29 b and miR-129-5P in HPMCs, ultimately reduce peritoneal fibrosis. These findings provide a potential theoretical basis for using matrine in the prevention and treatment of peritoneal fibrosis.
Subject(s)
Humans , Actins , Metabolism , Alkaloids , Therapeutic Uses , Cadherins , Metabolism , Cells, Cultured , Epithelial-Mesenchymal Transition , Epithelium , Fibrosis , Genetics , Metabolism , Lipopolysaccharides , Toxicity , MicroRNAs , Metabolism , Peritoneal Fibrosis , Drug Therapy , Quinolizines , Therapeutic UsesABSTRACT
AIM:To explore the effect of androgen receptor splice variant 7 ( AR-V7 ) on endocrine therapy resistance of prostate cancer cells and the resistance mechanisms .METHODS:Four prostate cancer cell lines were trans-fected with AR-V7 siRNA ( siAR-V7) using Lipofectamine 2000 kit, and the transfected cells were named as PC 3-siAR-V7, DU145-siAR-V7, LNCaP-siAR-V7 and ArCaP-siAR-V7 cells.The prostate cancer cells transfected with negative con-trol ( NC) siRNA served as negative controls .The expression of AR-V7 at mRNA and protein levels was detected by real-time PCR and Western blot , respectively .The cell viability and cell migration rate were measured by MTT assay and Tran-swell method, respectively.The promoter activity of AR and the protein levels of targeted prostate-specific antigen (PSA) and FK506-binding protein 5 (FKBP5) were monitored by luciferase reporter gene assay and Western blot , respectively. The bicalutamide-resistant cell line, LNCaP-DR, was constructed, and the subcellular localization of AR and AR-V7 pro-teins in LNCaP, LNCaP-siAR-V7 and LNCaP-DR cells was observed by the method of immunofluorescence .The protein in-teraction of AR-V7 and heat shock protein 90 ( HSP90) was determined by co-immunoprecipitation .RESULTS:The mR-NA level of AR-V7 in the 4 prostate cancer cell lines was significantly higher than that in normal prostate epithelial cell line RWPE-1 (P<0.05).The AR-V7 level, cell viability and cell migration rate in the cells transfected with siAR-V7 were notablely lowered compared with the NC siRNA-transfected cells (P<0.05).The cell viability was gradually decreased following with the increase in bicalutamide dose , and down-regulation of AR-V7 expression significantly enhanced the sensi-tivity to bicalutamide (P<0.05).Down-regulation of AR-V7 expression significantly inhibited AR promoter activity and reduced the protein levels of PSA and FKBP5 (P<0.05).The results of immunofluorescence observation showed that most AR and AR-V7 were mainly located in the nucleus , a few AR was located in the cytoplasm , and down-regulation of AR-V7 expression inhibited AR nuclear transport .AR was entirely located in the nucleus and the protein levels of AR-V7 was sig-nificantly increased in the bicalutamide-resistant cells .The interaction of endogenous AR-V7 with HSP90 was found in the prostate cancer cells .CONCLUSION: High AR-V7 level is found in the prostate cancer cells , and down-regulation of AR-V7 expression inhibits the cell viability and migration .High AR-V7 level is related to the bicalutamide resistance .The possible mechanism is that AR nuclear transport is mediated by the interaction of AR -V7 with HSP90 to activate AR signal pathway and regulate targeted gene transcriptional activity , thus resulting in drug resistance .
ABSTRACT
AIM:To explore the effect of androgen receptor splice variant 7 ( AR-V7 ) on endocrine therapy resistance of prostate cancer cells and the resistance mechanisms .METHODS:Four prostate cancer cell lines were trans-fected with AR-V7 siRNA ( siAR-V7) using Lipofectamine 2000 kit, and the transfected cells were named as PC 3-siAR-V7, DU145-siAR-V7, LNCaP-siAR-V7 and ArCaP-siAR-V7 cells.The prostate cancer cells transfected with negative con-trol ( NC) siRNA served as negative controls .The expression of AR-V7 at mRNA and protein levels was detected by real-time PCR and Western blot , respectively .The cell viability and cell migration rate were measured by MTT assay and Tran-swell method, respectively.The promoter activity of AR and the protein levels of targeted prostate-specific antigen (PSA) and FK506-binding protein 5 (FKBP5) were monitored by luciferase reporter gene assay and Western blot , respectively. The bicalutamide-resistant cell line, LNCaP-DR, was constructed, and the subcellular localization of AR and AR-V7 pro-teins in LNCaP, LNCaP-siAR-V7 and LNCaP-DR cells was observed by the method of immunofluorescence .The protein in-teraction of AR-V7 and heat shock protein 90 ( HSP90) was determined by co-immunoprecipitation .RESULTS:The mR-NA level of AR-V7 in the 4 prostate cancer cell lines was significantly higher than that in normal prostate epithelial cell line RWPE-1 (P<0.05).The AR-V7 level, cell viability and cell migration rate in the cells transfected with siAR-V7 were notablely lowered compared with the NC siRNA-transfected cells (P<0.05).The cell viability was gradually decreased following with the increase in bicalutamide dose , and down-regulation of AR-V7 expression significantly enhanced the sensi-tivity to bicalutamide (P<0.05).Down-regulation of AR-V7 expression significantly inhibited AR promoter activity and reduced the protein levels of PSA and FKBP5 (P<0.05).The results of immunofluorescence observation showed that most AR and AR-V7 were mainly located in the nucleus , a few AR was located in the cytoplasm , and down-regulation of AR-V7 expression inhibited AR nuclear transport .AR was entirely located in the nucleus and the protein levels of AR-V7 was sig-nificantly increased in the bicalutamide-resistant cells .The interaction of endogenous AR-V7 with HSP90 was found in the prostate cancer cells .CONCLUSION: High AR-V7 level is found in the prostate cancer cells , and down-regulation of AR-V7 expression inhibits the cell viability and migration .High AR-V7 level is related to the bicalutamide resistance .The possible mechanism is that AR nuclear transport is mediated by the interaction of AR -V7 with HSP90 to activate AR signal pathway and regulate targeted gene transcriptional activity , thus resulting in drug resistance .